Keystone Capital Partners, LLC, RANZ Group LLC, and Fredric Zaino filed an amended Schedule 13G with the SEC on November 5, 2026, reporting a beneficial ownership position of 419,298 shares of Onconetix, Inc. common stock as of September 30, 2026, and disclosing that each reporting person has ceased to be the beneficial owner of more than 5 percent of the common stock.

Key Highlights

  • Three reporting persons: Keystone Capital Partners, LLC, RANZ Group LLC, and Fredric Zaino each report beneficial ownership of 419,298 shares, representing 6.32% of Onconetix common stock.
  • Below-5% threshold crossed: The filing states that as of the date of filing, each of Keystone Capital Partners, RANZ Group LLC, and Fredric Zaino "has ceased to be the beneficial owner of more than 5 percent of the common stock."
  • No sole voting or dispositive power: All 419,298 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Excluded shares: The reported amount excludes 1,214,208 shares issuable upon exercise of warrants, 19,494 shares issuable upon conversion of preferred stock at an alternate conversion price of $0.51, and 97,726,577 shares issuable under a common stock purchase agreement, all subject to a 4.99% beneficial ownership cap.
  • Share count basis: The 6.32% percentage is calculated using 5,241,486 shares of common stock outstanding as of September 29, 2026, as reported in the company's Definitive Proxy Statement dated October 7, 2026.
  • Control structure: According to the filing, Keystone is managed by RANZ Group, which maintains investment and voting power over Keystone's securities, and Fredric Zaino controls RANZ Group.

Keystone Capital Partners and Affiliates Report Reduced Stake in Onconetix

According to the amended Schedule 13G filed with the SEC, Keystone Capital Partners, LLC, together with its affiliated entities RANZ Group LLC and individual Fredric Zaino, reported aggregate beneficial ownership of 419,298 shares of Onconetix, Inc. (NASDAQ:ONCO) common stock, par value $0.00001 per share, as of the event date of September 30, 2026. The filing identifies Onconetix's principal executive offices at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202, and the reporting persons' address as 139 Fulton Street, Suite 412, New York, NY 10038.

The filing discloses that RANZ Group and Mr. Zaino do not directly own any shares. Rather, Keystone holds the shares, Keystone is managed by RANZ Group, and Mr. Zaino controls RANZ Group. As a result, the filing states that RANZ Group and Mr. Zaino "may be deemed to own beneficially all of the Shares," but each of RANZ Group and Mr. Zaino "disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein."

The disclosed 419,298-share position is noted as excluding a substantial number of potential shares. Specifically, the filing states the reported amount excludes 1,214,208 shares issuable upon exercise of warrants held by Keystone, 19,494 shares issuable upon conversion of preferred stock held by Keystone at an alternate conversion price of $0.51, and 97,726,577 shares issuable pursuant to a common stock purchase agreement between the company and Keystone. The filing notes that each of these excluded instruments is "subject to a prohibition on issuance if such issuance would result in the holder beneficially owning over 4.99% of the common stock." Item 5 of the filing checks "Ownership of 5 percent or less of a class," consistent with each reporting person's statement that it has ceased to be the beneficial owner of more than 5 percent.

What Was Disclosed

Keystone Capital Partners, LLC, RANZ Group LLC, and Fredric Zaino filed an amended Schedule 13G disclosing 419,298 shares of Onconetix common stock, representing 6.32% of the class based on 5,241,486 shares outstanding, while each reporting person stated it has fallen below the 5% beneficial ownership threshold.